Completion of Acquisition or Disposition of Assets. The information contained above in

CEO, President, Chief Technology Officer, Chief Medical Officer, Director — Stephen From, Adam Sachs, Sammy Khalifa, Dr. Barry Greene, Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, Fuad Ahmad: All board members and key executives resigned or were terminated as part of a company transition.

Entry into a Material Definitive Agreement. On July 21, 2026, Vicarious Surgical, Inc. (the “Company” or “Vicarious”) held a Special Meeting of Stockholders (the “Special Meeting”) at which the Company’s stockholders approved the transfer of all or substantially all of the Company’s assets through an assignment for the benefit of creditors subject to the Company’s Board of Directors (the “Board”) determining that such action was in the best interests of the Company. On July 21, 2026, the Boar…

Chief Financial Officer — Sarah Romano: Sarah Romano resigned as Chief Financial Officer without a successor named.

Results of Operations and Financial Condition. On March 9, 2026, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the fiscal year and fourth fiscal quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subj…

Other Events As previously disclosed, on March 3, 2026, the New York Stock Exchange (the “NYSE”) notified the Company that the NYSE had determined to (A) immediately suspend trading in the Company’s common stock, par value $0.0001 per share (the “Common Stock”), due to a determination that the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000…

Adams Sachs, Sammy Khalifa: The executives agreed to voluntarily reduce their annual base salaries while maintaining target bonus and severance payment calculations based on previous salary levels.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 3, 2026, the New York Stock Exchange (the “NYSE”) notified Vicarious Surgical Inc. (the “Company”) that the NYSE had determined to (A) immediately suspend trading in the Company’s common stock, par value $0.0001 per share (the “Common Stock”), due to a determination that the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an averag…

Amendments to employment agreements for CEO and CFO, providing severance benefits.

Entry Into a Material Definitive Agreement. On December 12, 2025, Vicarious Surgical Inc., a Delaware corporation (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”) providing for the sale by the Company of its shares of Class A common stock, par value $0.0001 per share (the “Common Stock”), from time to time, through the Sales Agent, with certain limitations on the amount of Common Stock t…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 15, 2025, the NYSE notified the Company that the NYSE has determined to (a) commence proceedings to delist the Company’s warrants, with thirty warrants exercisable for one share of Common Stock, at an exercise price of $345.00 per share, and listed to trade on the NYSE under the symbol “RBOT.WS” (the “Public Warrants”) and (b) immediately suspend trading in the Public Warrants due…

Director — Beverly Huss, Randy Clark: Resigned as Directors in connection with a decision to reduce the Board size.

Results of Operations and Financial Condition. On November 12, 2025, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2025 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc…

Such disclosure includes, but is not limited to, the fact that the Common Warrants and the Common Warrant Shares are being issued in a private placement transaction and have not been registered under the Securities Act and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.

Entry into a Material Definitive Agreement. Registered Direct Offering and Concurrent Private Placement On October 7, 2025, Vicarious Surgical Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to issue to the Purchaser (i) in a registered direct offering, 588,300 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common S…

Director — Donald Tang: Mr. Tang resigned from the Board of Directors.

Results of Operations and Financial Condition. On August 12, 2025, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the second quarter ended June 30, 2025 and providing a business update. A copy of the press release issued on August 12, 2025 is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Chief Executive Officer and Director — Stephen From: Stephen From was appointed as the new Chief Executive Officer and Director of Vicarious Surgical Inc.

Change in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm. On July 7, 2025, the Company dismissed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm. The dismissal of Deloitte was approved by the audit committee (the “Audit Committee”) of the board of directors (the “Board”) of the Company. Deloitte’s audit report dated March 17, 2025 on the Company’s consolidated financial statements as of and f…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on April 10, 2025, Vicarious Surgical Inc. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company was no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact tha…

The filing details changes to the equity plan and non-employee director compensation policy.

Results of Operations and Financial Condition. On May 12, 2025, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2025 and providing a business update. A copy of the press release issued on May 12, 2025 is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…

of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act regardless of any general incorporation language in such filings. 1 Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K includes “forward-looking statements” within the meaning o…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 10, 2025, Vicarious Surgical, Inc. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company is no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact that the Company’s average…

President — Randy Clark: Mr. Randy Clark resigned as President and was appointed to the Board.